TY - JOUR
T1 - Intralymphatic administration of BCG in melanoma patients
AU - Cascinelli, Natale
AU - Balzarini, Gian Paolo
AU - Fontana, Vincenzo
AU - Orefice, Sergio
AU - Veronesi, Umberto
PY - 1977
Y1 - 1977
N2 - From November 1973 to December 1974, 20 patients with advanced malignant melanoma were treated with BCG given by intralymphatic route at the Cancer Institute of Milan. The lyophilized Pasteur BCG was used. Patients were treated with a single dose ranging from 0.2-80 mg. Patients' performance status was never severely impaired. The most frequent side effects were fever, lymphangitis, and lymph node enlargement. Variations were observed in white cell count, ERS and immunoglobulins; in no case did we find evidence of liver toxicity or tumor growth enhancement. It is concluded that the intralymphatic route is a safe way of administrating BCG.
AB - From November 1973 to December 1974, 20 patients with advanced malignant melanoma were treated with BCG given by intralymphatic route at the Cancer Institute of Milan. The lyophilized Pasteur BCG was used. Patients were treated with a single dose ranging from 0.2-80 mg. Patients' performance status was never severely impaired. The most frequent side effects were fever, lymphangitis, and lymph node enlargement. Variations were observed in white cell count, ERS and immunoglobulins; in no case did we find evidence of liver toxicity or tumor growth enhancement. It is concluded that the intralymphatic route is a safe way of administrating BCG.
UR - http://www.scopus.com/inward/record.url?scp=0017653087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017653087&partnerID=8YFLogxK
U2 - 10.1007/BF00205432
DO - 10.1007/BF00205432
M3 - Article
AN - SCOPUS:0017653087
VL - 2
SP - 157
EP - 161
JO - Cancer Immunology and Immunotherapy
JF - Cancer Immunology and Immunotherapy
SN - 0340-7004
IS - 3
ER -